Cosmos Health Regains Full Compliance With Nasdaq Listing Requirements
Cosmos Health Regains Full Compliance With Nasdaq Listing Requirements
CHICAGO, IL / ACCESSWIRE / August 23, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that the Company has regained compliance with Listing Rule 5250(c)(1) (the "Filing Rule"), in connection with the filing of its 2023 Annual Report on Form 10-K (the "Annual Report") and its financial results for the first quarter ended March 31, 2024, on Form 10-Q (the "First Quarter Report").
Cosmos Health Inc.（"Cosmos Health"或"公司"）（納斯達克：COSM）是一家多元化、垂直整合的全球醫療保健集團，從事創新研發、擁有自有藥品和保健品品牌、醫療產品製造和分銷，以及運營遠程醫療平台。宣佈公司已按照第5250(c)(1)號上市規則（"文件規則"）恢復合規，與2023年年度報告（"年度報告"）以及截至2024年3月31日的第一季度財務報告（"第一季度報告"）的提交有關。
On April 17 and May 21, 2024, the Company received notification letters (the "Notification Letters") from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") stating that it no longer met the periodic filing requirement for The Nasdaq Stock Market Filing Rule.
2024年4月17日和5月21日，公司收到了納斯達克股票市場（"納斯達克"）上市資格部門的通知函件（"通知函件"），稱其不再滿足納斯達克股票市場上市規則的定期報告要求。
Based on the August 5 and August 19, 2024, filings of the Company's Form 10-K for the year ended December 31, 2023, and Form 10-Q for the period ended March 31, 2024, Nasdaq has determined that the Company complies with the Filing Rule. Accordingly, this matter is now closed.
基於2024年8月5日和8月19日公司提交的截至2023年12月31日的10-k報告以及截至2024年3月31日的10-Q報告，納斯達克已確定公司符合規定。因此，此事現已結案。
Greg Siokas, CEO of Cosmos Health, stated: "We are extremely pleased to have regained compliance with Nasdaq, both in terms of filing our Annual Report and First Quarter Report, and meeting Nasdaq's Minimum Bid Price Rule earlier in July. As a result, Cosmos is now fully compliant with all Nasdaq listing requirements."
Cosmos Health的CEO Greg Siokas表示：「我們非常高興重新符合納斯達克的要求，無論是提交年度報告和第一季度報告，還是在7月份早些時候滿足納斯達克的最低競價規則。因此，Cosmos現已完全符合納斯達克的所有上市要求。」
About Cosmos Health Inc.
Cosmos Health Inc.（納斯達克:COSM）成立於2009年，總部位於內華達州，是一家全球健康醫療集團公司。公司擁有一系列專有藥品和保健品牌，包括Sky Premium Life，Mediterranation，bio-bebe和C-Sept。公司的子公司Cana Laboratories S.A.獲得歐洲GMP許可和歐洲藥品管理局認證，生產醫藥品、食品補充劑、化妝品、生物滅菌劑和醫療設備等產品，並經營歐盟內的銷售。此外，Cosmos Health還通過希臘和英國的子公司向零售藥店和批發經銷商銷售廣泛的藥品和非處方藥品，包括品牌仿製藥和OTC藥品。此外，該公司還與人工智能藥物再利用技術合作，專注於研發針對肥胖症、糖尿病和癌症等主要健康障礙的研發合作，並專注於研發新的專利營養保健品、特殊植物提取物、專有複合仿製藥和創新非處方藥品。Cosmos Health還通過收購總部位於德克薩斯州的ZipDoctor，Inc進入了遠程醫療領域。公司正在全球範圍內擴張，並在希臘的塞薩洛尼基和雅典、英國的哈洛等地設有辦事處和配送中心。 更多信息請訪問公司網站：，以及LinkedIn和X。
Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life, Mediterranation, bio-bebe and C-Sept. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at , , , , as well as LinkedIn and X.
Cosmos Health公司（Nasdaq：COSM）成立於2009年，總部位於內華達州，是一家多元化、垂直一體化的全球醫療保健集團，擁有一系列專有藥品和營養保健品品牌，包括Sky Premium Life，Mediterranation，bio-bebe和C-Sept。通過其子公司Cana Laboratories S.A.，該公司生產製藥、食品補充劑、化妝品、生物農藥和醫療設備等，持有歐洲藥品管理局（EMA）頒發的歐洲GMP證書，滿足GMP標準。Cosmos Health公司還通過旗下位於希臘和英國的子公司向零售藥店和批發商銷售廣泛的藥品和非藥品醫療產品。此外，該公司還建立了針對肥胖症、糖尿病和癌症等重大健康問題的研發夥伴關係，加強人工智能藥物再利用技術，專注於研發新型專利營養保健品、特殊根部提取物、專有複雜化學品和創新的非處方產品。Cosmos Health公司還通過收購總部位於美國德克薩斯州的ZipDoctor公司進入了遠程醫療領域。
SOURCE: Cosmos Health Inc.
資訊來源：Cosmos Health Inc.
譯文內容由第三人軟體翻譯。